C-Reactive Protein in Atherosclerosis-More Than a Biomarker, but Not Just a Culprit

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39077585

Authors

Kursat Kirkgoz

Affiliations

Soon will be listed here.

Abstract

C-reactive protein (CRP) is a pentraxin that is mainly synthesized in the liver in response to inflammatory cytokines. It exists in two functionally and structurally distinct isoforms. The first is a highly pro-inflammatory and mostly tissue-bound monomeric isoform (mCRP). The second is circulating pentameric CRP (pCRP), which also serves as a substrate for the formation of mCRP. CRP is elevated during inflammatory conditions and is associated with a higher risk of cardiovascular disease. The aim of this review is to examine the current state of knowledge regarding the role of these two distinct CRP isoforms on atherogenesis. This should allow further evaluation of CRP as a potential therapeutic target for atherosclerosis. While it seems clear that CRP should be used as a therapeutic target for atherosclerosis and cardiovascular disease, questions remain about how this can be achieved. Current data suggests that CRP is more than just a biomarker of atherosclerosis and cardiovascular disease. Indeed, recent evidence shows that mCRP in particular is strongly atherogenic, whereas pCRP may be partially protective against atherogenesis. Thus, further investigation is needed to determine how the two CRP isoforms contribute to atherogenesis and the development of cardiovascular disease.

Citing Articles

C-reactive protein-induced injury in -infected lung epithelial cells is mediated by the P38 MAPK/mitochondrial apoptosis pathway.

Li L, Zhang Y, Zhao L, Shi Y Microbiol Spectr. 2025; 13(3):e0162624.

PMID: 39932324 PMC: 11878036. DOI: 10.1128/spectrum.01626-24.

Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment.

Prasad K Int J Angiol. 2024; 33(4):271-281.

PMID: 39502349 PMC: 11534478. DOI: 10.1055/s-0044-1788296.

References

Barbosa S, Lins L, Fonseca F, Matos L, Aguirre A, Bianco H . Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sci. 2013; 92(14-16):845-51. DOI: 10.1016/j.lfs.2013.02.018. View

Volanakis J . Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001; 38(2-3):189-97. DOI: 10.1016/s0161-5890(01)00042-6. View

Ruan Q, Yang K, Wang W, Jiang L, Song J . Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5):846-848. PMC: 7080116. DOI: 10.1007/s00134-020-05991-x. View

Fu T, Borensztajn J . Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J. 2002; 366(Pt 1):195-201. PMC: 1222776. DOI: 10.1042/BJ20020045. View

Arnaud C, Burger F, Steffens S, Veillard N, Nguyen T, Trono D . Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005; 25(6):1231-6. DOI: 10.1161/01.ATV.0000163840.63685.0c. View

Ji S, Wu Y, Zhu L, Potempa L, Sheng F, Lu W . Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J. 2006; 21(1):284-94. DOI: 10.1096/fj.06-6722com. View

Chen J, Huang L, Song M, Yu S, Gao P, Jing J . C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells. J Cardiovasc Pharmacol. 2009; 53(5):359-67. DOI: 10.1097/FJC.0b013e31819b5438. View

Kather M, Zeller J, Plattner D, Breit B, Kreuzaler S, Krippner G . Pharmacokinetic study of the novel phosphocholine derivative 3-dibutylaminopropylphosphonic acid by LC-MS coupling. J Chromatogr B Analyt Technol Biomed Life Sci. 2021; 1186:122998. DOI: 10.1016/j.jchromb.2021.122998. View

Verma S, Wang C, Li S, Dumont A, Fedak P, Badiwala M . A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106(8):913-9. DOI: 10.1161/01.cir.0000029802.88087.5e. View

10.

Boras E, Slevin M, Alexander M, Aljohi A, Gilmore W, Ashworth J . Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway. Cytokine. 2014; 69(2):165-79. DOI: 10.1016/j.cyto.2014.05.027. View

11.

Badimon L, Vilahur G . Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014; 276(6):618-32. DOI: 10.1111/joim.12296. View

12.

Nayeri H, Naderi G, Saleh Moghadam M, Mohamadzadeh S, Boshtam M, Jafari Dinani N . Effect of CRP on Some of the in vitro Physicochemical Properties of LDL. ARYA Atheroscler. 2012; 6(3):85-9. PMC: 3347822. View

13.

Xu J, Lu X, Shi G . Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci. 2015; 16(5):11574-608. PMC: 4463718. DOI: 10.3390/ijms160511574. View

14.

Li L, Roumeliotis N, Sawamura T, Renier G . C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res. 2004; 95(9):877-83. DOI: 10.1161/01.RES.0000147309.54227.42. View

15.

Clyne B, Olshaker J . The C-reactive protein. J Emerg Med. 1999; 17(6):1019-25. DOI: 10.1016/s0736-4679(99)00135-3. View

16.

Schwedler S, Kuhlencordt P, Ponnuswamy P, Hatiboglu G, Quaschning T, Widder J . Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species. Atherosclerosis. 2007; 195(2):e76-84. DOI: 10.1016/j.atherosclerosis.2007.06.013. View

17.

Verma S, Li S, Badiwala M, Weisel R, Fedak P, Li R . Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105(16):1890-6. DOI: 10.1161/01.cir.0000015126.83143.b4. View

18.

Kotlyarov S . Immune Function of Endothelial Cells: Evolutionary Aspects, Molecular Biology and Role in Atherogenesis. Int J Mol Sci. 2022; 23(17). PMC: 9456046. DOI: 10.3390/ijms23179770. View

19.

Kostner A, Fuglestad A, Georgsen J, Nielsen P, Bang Christensen K, Zibrandtsen H . Fueling the flames of colon cancer - does CRP play a direct pro-inflammatory role?. Front Immunol. 2023; 14:1170443. PMC: 10065292. DOI: 10.3389/fimmu.2023.1170443. View

20.

Voloshyna I, Littlefield M, Reiss A . Atherosclerosis and interferon-γ: new insights and therapeutic targets. Trends Cardiovasc Med. 2013; 24(1):45-51. PMC: 3844070. DOI: 10.1016/j.tcm.2013.06.003. View